Navigation Links
Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b

Helix BioPharma Corp.

AURORA, ON, March 30, 2007 /PRNewswire-FirstCall/ - Helix today announced positive results from its phase II clinical study of its Topical Interferon Alpha-2b in women with human papilloma virus (HPV) induced low-grade cervical lesions.

The study showed a clinically efficacious response to treatment in nearly half of the treated patients. In addition, the product demonstrated an excellent safety profile, with no significant local intolerance or drug-related serious adverse event observations.

"Treated patients responded well, both in terms of efficacy and safety to this new investigational therapeutic," said Prof. Dr. med. Achim Schneider M.P.H., a world expert in the field of cervical cancer and Director of the Department of Gynaecology at the Charite University Hospital in Berlin. "Helix's product shows real promise as a practical and effective pharmaceutical means of preventing cervical cancer development in women presenting with HPV-induced cervical lesions", continued Prof. Schneider.

About the Clinical Study

A total of 41 women with cytologically confirmed, HPV-induced low-grade squamous intraepithelial lesions (LSIL) of the cervix were studied across four sites in Germany. Twenty women received Topical Interferon Alpha-2b, self-administered intravaginally three times per week for a period of 6 weeks with a follow-up evaluation at 12 weeks, compared with 21 separately studied women who received no treatment whatsoever over the same study period.

The primary endpoint and main outcome for both groups was the Pap-response rate defined as the proportion of patients with resolution of their abnormal Pap smear LSIL cytology to normal during the 12 week study duration. Pap smear normalization was considered to occur if the patient's Pap smear improved to group II or better from any of Pap smear groups IIW through IIID as per the common European stan
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
2. Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy
3. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
4. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
7. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
8. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
9. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
10. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Animal Health ... About Animal Health Animal health refers ... or treat animals to enhance their quality of ... of animal food. The Global Animal Health market ...
(Date:8/27/2014)... Kewaunee Scientific Corporation (Nasdaq: KEQU ... quarterly cash dividend by 9% to twelve cents per ... with the dividend payable on September 22, 2014 to ... September 8, 2014. About Kewaunee Scientific ... Corporation is a recognized global leader in the design, ...
(Date:8/27/2014)... , Aug. 27, 2014  UBM Medica US announces ... online community for medical imaging professionals, presents special reporting ... Medical Imaging Management,s 2014 Annual Meeting . ... , 11 Principles of Successful Labor ... to greater profitability. , Why Don,t Patients ...
Breaking Medicine Technology:Global Animal Health Market 2014-2018 2Global Animal Health Market 2014-2018 3Global Animal Health Market 2014-2018 4Global Animal Health Market 2014-2018 5Global Animal Health Market 2014-2018 6Global Animal Health Market 2014-2018 7Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3
... and INDIANAPOLIS, Ind., May 5 A new substudy from ... showed that patients who took prasugrel and had a reduced ... risk of cardiovascular death, heart attack or stroke compared with ... were published online in Circulation on May 4, ...
... Oramed Pharmaceuticals, Inc.,(OTC: ORMP) ( http://www.oramed.com ), a ... clinical trials will commence this week on 30 ... evaluate the safety,tolerability and efficacy of its oral ... (CRO) located in Johannesburg,South Africa, will oversee the ...
Cached Medicine Technology:New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel 2New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel 3New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel 4New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel 5Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule 2
(Date:8/27/2014)... Home Care Assistance of Scottsdale , ... proud to announce the next installment in its renowned ... Dr. Suzanne Steinbaum, attending cardiologist and Director of Women’s ... City, National Spokesperson for the American Heart Association’s Go ... issues surrounding women and heart disease, what heart disease ...
(Date:8/27/2014)... of clinical trial participation in the largest ongoing observational ... are not representative of the larger patient base, according ... Dr. Jay Udell. The study authors call into question ... population, and suggest the use of broader enrollment criteria ... "We know that clinical trials can be tremendously expensive ...
(Date:8/27/2014)... tested an advanced statistical model to evaluate the ... as published yesterday in Human Genetics . ... in current analyses. Complex diseases like cancer usually ... factors. When many such combinations are studied, identifying ... combinations among affected individuals becomes difficult. In this ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Cash House ... impact on the overall upkeep of the shelter including new ... importantly helping to change the lives of each youth who ... 35 bed emergency shelter for youth ages 16-25. Not only ... many programs and resources for the youth who come through ...
(Date:8/27/2014)... Lighthouse Payment Services Inc ., a leader ... exhibit its image-based lockbox services at the Independent Bankers ... in beautiful Lake Placid, New York from September 7th ... at the Lake Placid Convention Center and will feature ... addition to a variety of vendors exhibiting the latest ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Cash House a Major Supporter of Horizons for Youth 2Health News:Cash House a Major Supporter of Horizons for Youth 3
... (Carlsbad, CA) and its development partner, Logical Therapeutics, Inc. ... active comparator study of LT-NS001 (formerly MX-1094) vs naproxen, ... LT-NS001 is a novel, patented NCE prodrug of the ... developed to significantly reduce the GI safety risks, including ...
... 30-Year Finance Executive Veteran Adds Public Accounting, Executive ... Smith announced today that Dave Watkins has been ... responsible for overseeing all Company financial functions, including ... forecasts and tax planning. H. D. Smith ...
... Time Spent Caring for Parents with Alzheimer,s in Heartfelt New ... memoirs, "36 Days Apart: A memoir of a daughter, her ... Life, Love and Death" ( published by AuthorHouse ... of her mother and father, both of whom were diagnosed ...
... - Discovery Health,s Seventh Annual Programming Event Presents Baby ... 14, through Friday, June 19 - SILVER SPRING, Md., ... the third week of June to deliver the network,s ... pregnancies, to surprise deliveries, to expectant mothers big and ...
... prebiotics market is diversifying and expanding in ... and beverage industry, with several exciting developments ... and the expansion of prebiotic ingredients into ... and meat products.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )New prebiotic ...
... of 14 Hydroxycut products, consumers who have suffered injuries from using ... products liability attorney to determine if he/she is eligible for compensation. ... , ... San Diego, CA (PRWEB) May 26, 2009 ...
Cached Medicine News:Health News:Medinox Announces Clinical Results of Naproxen Prodrug 2Health News:H. D. Smith Appoints Dave Watkins Chief Financial Officer 2Health News:New Memoir Details Effects of Alzheimer's on Family 2Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 2Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 3Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 4Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 2Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 3Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 4Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 5Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 6Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 7Health News:LawInfo Provides Access to Qualified Hydroxycut Litigation Attorneys Nationwide 2
... (Penicillin G) inhibits bacterial ... synthesis. Streptomycin belongs to ... inhibits bacterial growth by ... is used for prevention ...
...
Contains 10,000 units of penicillin (base), 10,000 g of streptomycin (base), and 25 g of amphotericin B/ml utilizing penicillin G (sodium salt), streptomycin sulfate, and amphotericin B as Fungizone ...
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
Medicine Products: